Search

Your search keyword '"von Amsberg G"' showing total 172 results

Search Constraints

Start Over You searched for: Author "von Amsberg G" Remove constraint Author: "von Amsberg G"
172 results on '"von Amsberg G"'

Search Results

3. Utilizing patient-derived organoids of prostate cancer to predict functional homologous recombination repair deficiency and targeted therapy response

11. 1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial

12. Bosutinib in the management of chronic myelogenous leukemia

17. Docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer: a real-life analysis

18. Therapiesituation beim metastasierten kastrationsnaiven Prostatakarzinom (mCNPC) und die Auswirkungen im klinischen Alltag

19. Abiraterone versus Docetaxel in der Erstlinientherapie des metastasierten hormonsensitiven Prostatakarzinoms – ein multizentrischer Vergleich

20. 1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial

24. Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine

25. P063 - Docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer: a real-life analysis

26. Advanced Prostate Cancer Consensus Conference 2017. Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts

27. Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom

28. Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia

31. The Inhibitory Activity of Luzonicosides from the Starfish Echinaster luzonicus against Human Melanoma Cells

32. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer

33. Applications of Nanopore sequencing in precision cancer medicine.

34. Lectins CGL and MTL, representatives of mytilectin family, exhibit different antiproliferative activity in Burkitt's lymphoma cells.

35. [Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors].

36. Stonikacidin A, an Antimicrobial 4-Bromopyrrole Alkaloid Containing L-Idonic Acid Core from the Northwestern Pacific Marine Sponge Lissodendoryx papillosa .

37. Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial.

38. Master corepressor inactivation through multivalent SLiM-induced polymerization mediated by the oncogene suppressor RAI2.

39. Synthesis and new DNA targeting activity of 6- and 7-tert-butylfascaplysins.

40. A Combined Cyto- and Histopathological Diagnostic Approach Reduces Time to Diagnosis and Time to Therapy in First Manifestation of Metastatic Spinal Disease: A Cohort Study.

41. Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery.

42. [Molecular testing of prostate cancer: timing, methods and consequences].

43. [Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].

44. [Advanced renal cell carcinoma - an overview of current systemic therapy].

45. Anticancer Activity of the Marine Triterpene Glycoside Cucumarioside A 2 -2 in Human Prostate Cancer Cells.

46. Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.

47. [Metastatic castration-resistant prostate cancer-emerging trends in therapy].

48. Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models.

49. [Sequential therapy of advanced bladder cancer after prior perioperative systemic treatment : Recommendations from the Interdisciplinary Bladder Carcinoma Working Group (IABC) of the DKG e. V.]

50. Preclinical Comparison of the 64 Cu- and 68 Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [ 68 Ga]Ga-AMTG PET/CT.

Catalog

Books, media, physical & digital resources